Clinical Trial Update: Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effect of morphine on dyspnea and 6-minute walk distance in patients with pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Morphine (morphine)

Snippet

Sponsor: John Granton | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: UNKNOWN